Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
20.15
+0.29 (1.46%)
At close: Mar 5, 2026, 4:00 PM EST
20.10
-0.05 (-0.25%)
Pre-market: Mar 6, 2026, 7:03 AM EST
Apellis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for Apellis Pharmaceuticals stock have an average target of 31.89, with a low estimate of 18 and a high estimate of 52. The average target predicts an increase of 58.26% from the current stock price of 20.15.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Apellis Pharmaceuticals stock from 20 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 6 | 6 | 6 |
| Buy | 7 | 7 | 6 | 5 | 5 | 5 |
| Hold | 8 | 9 | 8 | 8 | 8 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 20 | 21 | 20 | 20 | 20 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $36 → $37 | Buy | Maintains | $36 → $37 | +83.62% | Mar 5, 2026 |
| Mizuho | Mizuho | Hold Maintains $19 → $20 | Hold | Maintains | $19 → $20 | -0.74% | Mar 5, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $45 → $44 | Strong Buy | Maintains | $45 → $44 | +118.36% | Feb 25, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $22 → $21 | Hold | Maintains | $22 → $21 | +4.22% | Feb 25, 2026 |
| Wedbush | Wedbush | Hold Maintains $20 → $18 | Hold | Maintains | $20 → $18 | -10.67% | Feb 25, 2026 |
Financial Forecast
Revenue This Year
881.56M
from 1.00B
Decreased by -12.18%
Revenue Next Year
1.04B
from 881.56M
Increased by 17.97%
EPS This Year
-1.19
from 0.17
EPS Next Year
-0.33
from -1.19
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.0B | 1.3B | |||
| Avg | 881.6M | 1.0B | |||
| Low | 778.6M | 855.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.0% | 45.8% | |||
| Avg | -12.2% | 18.0% | |||
| Low | -22.4% | -2.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.38 | 1.09 | |||
| Avg | -1.19 | -0.33 | |||
| Low | -2.15 | -1.98 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.